Iamgold Corporation Ordinary Shares vs Oruka Therapeutics Inc. Common Stock — how do they compare? Iamgold Corporation Ordinary Shares trades at $17.4 (market cap $9.73B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: Iamgold Corporation Ordinary Shares is the larger of the two by market cap, and Oruka Therapeutics Inc. Common Stock is more actively traded (685,276 versus 5,625,762). Which is the better fit depends on your goals — on Pluang, investors hold Iamgold Corporation Ordinary Shares for 6 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| IAG | ORKA | |
|---|---|---|
Market Cap | $9.73B | $5.08B |
Volume | 5,625,762 | 685,276 |
Sector | Basic Materials | Health |
52-Week High | $24.57 | $113.08 |
52-Week Low | $10.96 | $26.19 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $9.77B | $4.21B |
Signals from Pluang's Aura AI — not financial advice
IAG trades at $18.27, down 1.62% today, with technical indicators showing a neutral bias. The company demonstrates strong fundamentals with a P/E of 9.23, net income margin of 31.4%, and ROE of 29.53%. Recent earnings show mixed results with two beats and one miss in the last three quarters. Analyst consensus is moderately bullish with a $22.00 price target, representing 20% upside potential from current levels.
IAG presents a compelling value opportunity with attractive valuation metrics and strong profitability. Key catalysts include Q3 2026 earnings release in November and operational optimization initiatives. Risks include commodity price volatility, execution challenges at mining operations, and potential cost pressures from rising fuel prices that could impact profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
IAMGOLD is a gold mining company with operations in Canada. It also explores and develops gold properties.
Read more on IAG →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →